Tags

Type your tag names separated by a space and hit enter

Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Arch Dermatol 2007; 143(1):45-50AD

Abstract

OBJECTIVE

To assess risks for developing second malignancies in patients with mycosis fungoides or Sézary syndrome.

DESIGN

Retrospective study of 2 cohorts.

SETTING

Nine population-based US cancer registries that constitute the Surveillance, Epidemiology, and End Results Program (SEER-9), and Stanford University referral center cohort of patients with cutaneous lymphoma. Patients with mycosis fungoides or Sézary syndrome from the SEER-9 registry diagnosed and followed up from 1984 through 2001 and from the Stanford University cohort diagnosed and followed up from 1973 through 2001.

MAIN OUTCOME MEASURES

Relative risk was estimated using the standardized incidence ratio (SIR). The expected cancer incidence for both cohorts was calculated using age-, sex-, race-, and calendar year-specific SEER-9 incidence rates for the general population. Nonmelanoma skin cancers were excluded because these cancers are not routinely reported by the SEER database.

RESULTS

In the SEER-9 cohort (n = 1798), there were 197 second instances of cancer (SIR = 1.32; 95% confidence interval [CI], 1.15-1.52) at all sites. Significantly elevated risk (P<.01) was observed for Hodgkin disease (6 cases; SIR = 17.14; 95% CI, 6.25-37.26) and non-Hodgkin lymphoma (27 cases; SIR = 5.08; 95% CI, 3.34-7.38). Elevated risk (P<.05) was also observed for melanoma (10 cases; SIR = 2.60; 95% CI, 1.25-4.79), and urinary cancer (21 cases; SIR = 1.74; 95% CI, 1.08-2.66). In the Stanford University cohort (n = 429), there were 37 second instances of cancer (SIR = 1.04; 95% CI, 0.76-1.44). Elevated risk (P<.01) was observed for Hodgkin disease (3 cases; SIR = 27.27; 95% CI, 5.35-77.54). Elevated risk (P<.05) was also observed for biliary cancer (2 cases; SIR = 11.76; 95% CI, 1.51-42.02).

CONCLUSION

Updated SEER (population based) and Stanford (clinic based) data confirm the generalizability of earlier findings of increased risk of lymphoma in patients with mycosis fungoides or Sézary syndrome.

Authors+Show Affiliations

Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17224541

Citation

Huang, Kathie P., et al. "Second Lymphomas and Other Malignant Neoplasms in Patients With Mycosis Fungoides and Sezary Syndrome: Evidence From Population-based and Clinical Cohorts." Archives of Dermatology, vol. 143, no. 1, 2007, pp. 45-50.
Huang KP, Weinstock MA, Clarke CA, et al. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol. 2007;143(1):45-50.
Huang, K. P., Weinstock, M. A., Clarke, C. A., McMillan, A., Hoppe, R. T., & Kim, Y. H. (2007). Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Archives of Dermatology, 143(1), pp. 45-50.
Huang KP, et al. Second Lymphomas and Other Malignant Neoplasms in Patients With Mycosis Fungoides and Sezary Syndrome: Evidence From Population-based and Clinical Cohorts. Arch Dermatol. 2007;143(1):45-50. PubMed PMID: 17224541.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. AU - Huang,Kathie P, AU - Weinstock,Martin A, AU - Clarke,Christina A, AU - McMillan,Alex, AU - Hoppe,Richard T, AU - Kim,Youn H, PY - 2007/1/17/pubmed PY - 2007/2/15/medline PY - 2007/1/17/entrez SP - 45 EP - 50 JF - Archives of dermatology JO - Arch Dermatol VL - 143 IS - 1 N2 - OBJECTIVE: To assess risks for developing second malignancies in patients with mycosis fungoides or Sézary syndrome. DESIGN: Retrospective study of 2 cohorts. SETTING: Nine population-based US cancer registries that constitute the Surveillance, Epidemiology, and End Results Program (SEER-9), and Stanford University referral center cohort of patients with cutaneous lymphoma. Patients with mycosis fungoides or Sézary syndrome from the SEER-9 registry diagnosed and followed up from 1984 through 2001 and from the Stanford University cohort diagnosed and followed up from 1973 through 2001. MAIN OUTCOME MEASURES: Relative risk was estimated using the standardized incidence ratio (SIR). The expected cancer incidence for both cohorts was calculated using age-, sex-, race-, and calendar year-specific SEER-9 incidence rates for the general population. Nonmelanoma skin cancers were excluded because these cancers are not routinely reported by the SEER database. RESULTS: In the SEER-9 cohort (n = 1798), there were 197 second instances of cancer (SIR = 1.32; 95% confidence interval [CI], 1.15-1.52) at all sites. Significantly elevated risk (P<.01) was observed for Hodgkin disease (6 cases; SIR = 17.14; 95% CI, 6.25-37.26) and non-Hodgkin lymphoma (27 cases; SIR = 5.08; 95% CI, 3.34-7.38). Elevated risk (P<.05) was also observed for melanoma (10 cases; SIR = 2.60; 95% CI, 1.25-4.79), and urinary cancer (21 cases; SIR = 1.74; 95% CI, 1.08-2.66). In the Stanford University cohort (n = 429), there were 37 second instances of cancer (SIR = 1.04; 95% CI, 0.76-1.44). Elevated risk (P<.01) was observed for Hodgkin disease (3 cases; SIR = 27.27; 95% CI, 5.35-77.54). Elevated risk (P<.05) was also observed for biliary cancer (2 cases; SIR = 11.76; 95% CI, 1.51-42.02). CONCLUSION: Updated SEER (population based) and Stanford (clinic based) data confirm the generalizability of earlier findings of increased risk of lymphoma in patients with mycosis fungoides or Sézary syndrome. SN - 0003-987X UR - https://www.unboundmedicine.com/medline/citation/17224541/Second_lymphomas_and_other_malignant_neoplasms_in_patients_with_mycosis_fungoides_and_Sezary_syndrome:_evidence_from_population_based_and_clinical_cohorts_ L2 - https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/archderm.143.1.45 DB - PRIME DP - Unbound Medicine ER -